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http://dx.doi.org/10.1016/j.asjsur.20Summary Perivascular epithelioid cell tumor (PEComa) is a rare tumor. Here, we present
data regarding clinical presentations, diagnoses, management, and prognosis of five cases of
hepatic PEComa between January 2002 and December 2008. Ultrasonography showed hypere-
choic masses in all patients. Precontrast computed tomography (CT) showed that all lesions
scanned were heterogeneous in density and were heterogeneously enhanced in arterial phase
images. In two cases, magnetic resonance imaging showed hypointensity on T1-weighted
images and hyperintensity on T2-weighted images. In enhanced scanning, lesions showed
asymmetrical enhancement during arterial phase imaging. All tumors were composed of
varying proportions of smooth muscle, adipose tissue, and thick-walled blood vessels, and
showed positive immunohistochemical staining for Human Melanoma Black-45. All patients
underwent hepatectomy, and there was no evidence of recurrence or metastasis during the
follow-up period.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Perivascular epithelioid cell tumor (PEComa) is a rare tumor
that derives from mesenchyma. PEComa occurs mostof General Surgery, Shengjing H
g (Z. Liu).
n Surgical Association. Published
12.06.010commonly in the kidneys. Hepatic PEComa represents the
second most common site of involvement. Rare occurrences
at many other sites have been reported, including the
uterus, retroperitoneum, mediastinum, renal capsule, the
nasopharyngeal cavity, the buccal mucosa, the hard palate,ospital, China Medical University, No. 36 Sanhao Street, Shenyang
by Elsevier Taiwan LLC. All rights reserved.
Hepatic perivascular epithelioid cell tumor 59penis, vagina, fallopian tube, abdominal wall, skin,
stomach, and spinal cord.1e3 Most hepatic PEComas are
benign. Malignant hepatic PEComa is extremely rare; only
four cases have been reported.4 Hepatic PEComa is
composed of varying amounts of smooth muscle cells,
adipose tissue, and blood vessels. It shows typical immu-
nophenotypic features of both smooth muscle and mela-
nocytic differentiation.5 This heterogeneity makes the
preoperative diagnosis by imaging, needle biopsy, and
other techniques difficult. Because of low morbidity, there
has been a lack of comprehensive understanding of this
hepatic lesion.
In this article, we will present five pathologically proven
cases of hepatic PEComa in our hospital between 2002 and
2008, retrospectively discuss their clinical and histologic
features, and review the literature.
2. Patients and methods
2.1. Clinical history and presentation
Five surgically resected specimens of hepatic PEComa were
available at the Shengjing Hospital, China Medical Univer-
sity, from five individual cases between January 2002 and
December 2008. The specimens were from one male and
four female patients, ranging in age from 26 to 57 years. In
all patients, liver function and a-fetoprotein were normal.
None of the patients were complicated with tuberous
sclerosis complex (TSC), hepatitis B virus (HBV), or hepatitis
C virus (HCV). One female patient was complicated with
renal PEComa. None of the patients had received preop-
erative therapy. Two patients had symptoms caused by the
large space-occupying lesion, but the other three patients
were asymptomatic and were discovered incidentally
during routine physical examination. One case had multiple
tumors and the others had a sporadic tumor.
All tissues were reviewed independently by two pathol-
ogists. Histopathological diagnosis was made according to
the World Health Organization classification of tumors of
the liver and intrahepatic bile ducts.6 The most important
diagnostic criterion was the presence of Human Melanoma
Black-45 (HMB-45)-positive myoid cells.
2.2. Imaging representation
All patients received ultrasonography and computed
tomography (CT) examinations, but only two patients
received magnetic resonance imaging (MRI). On sonog-
raphy, the tumors were seen as a hyperechoic mass, either
homogeneous or heterogeneous. The lesions exhibited well-
demarcated mass with heterogeneous density in plain CT
scan. In arterial CT, the lesions were heterogeneously
enhanced. In the portal venous phase, the lesions returned
to an isoattenuating state (Fig. 1). In a 37-year-old woman
complicated with renal PEComa, MRI showed heteroge-
neous hypointensity on T1-weighted images (T1WIs) and
hyperintensity on T2-weigthed images (T2WI). After fat
saturation, hyperintensity on T2WI in the liver lesion
remained, but T2WI in the renal lesion showed hypointen-
sity. In enhanced scanning, the lesions showed asymmet-
rical enhancement in arterial phase images (Fig. 2). In a 52-year-old woman with multiple liver lesions, MRI showed
a lesion located on the left lobe and S8 of the liver. The
lesions showed heterogeneous hypointensity on T1WI and
heterogeneous hyperintensity on T2WI. After fat satura-
tion, hyperintensity on T2WI remained. In enhanced scan-
ning, the lesions showed asymmetrical enhancement in
arterial phase images (Fig. 3). Prior to operation, one case
was diagnosed with hepatic PEComa, three cases with
hepatocellular carcinoma, and one case with hepatic
adenomata.
2.3. Pathologic findings
2.3.1. Gross
The tumors were all circumscribed, either unencapsulated
or encapsulated. The cut surface was described as soft,
with color descriptions ranging from yellow to dark red, and
areas of hemorrhage were present in three cases. In a case
of multiple PEComa, two lesions were 2.4 and 4 cm in their
greatest dimension. The largest lesion was 23  16  6 cm3
and had a capsule.
2.3.2. Histopathology
In all cases, interpretation of frozen sectioning performed
during surgery suggested benign hepatic neoplasm; the final
diagnosis was deferred to the analysis of permanent
sections. Routine histopathological examination with
hematoxylin and eosin staining was performed. Immuno-
histochemical studies were performed by streptavidin
peroxidase conjugated method, using a panel of antibodies
[HMB-45, smooth muscle actin (SMA), melan-A, vimentin,
CK8/18, hepatocyte, and S100] in all of the tumor tissues.
Microscopically, the tumor was composed of a mixture of
thick-walled blood vessels, mature adipose tissue, and
irregularly arranged bundles of smooth muscle. Extra-
medullary hematopoiesis was focally noted. Some cells
were large, with clear cytoplasm and prominent peri-
nuclear eosinophilic condensations (Fig. 4).
Immunohistochemically, the tumor cells were immuno-
reactive for HMB-45 in all five cases, for SMA in four cases,
for vimentin in one case, and for melan-A in two cases
(Fig. 5). The tumor cells were negative for S100, hepato-
cyte, and CK8/18.
2.4. Treatment and follow-up
All patients received hepatectomy. Partial hepatectomy
was performed in three patients, left hepatic lobectomy
and partial right hepatectomy in a case of multiple hepatic
PEComa, and partial hepatectomy and partial nephrectomy
in a case complicated with renal PEComa. Prior to this
study, all patients received a follow-up examination. The
time of follow-up ranged from 29 to 101 months. No
recurrence or metastasis was found in any patient, and liver
function was normal during the follow-up period.
3. Discussion
The term of “perivascular epithelioid cell” (PEC) was first
proposed by Bonetti et al in 1992.7 After several years,
Zamboni et al8 coined the term “PEComa” for the family of
Figure 1 CT image of hepatic PEComa. (A) Plain CT scan showed a well-demarcated mass with heterogeneous density in the liver.
(B) Contrast-enhanced CT scan of the same lesion showed a heterogeneously enhanced lesion in the arterial phase. (C) Contrast-
enhanced CT scan of the same lesion showed the lesion returned to an isoattenuating state in the portal phase. CT Z computed
tomography.
60 Z. Liu et al.related mesenchymal neoplasms containing the distinctive
“PEC.” This type of tumor consists of three components:
thick-walled, often hyalinized blood vessels; smooth
muscle cells; and adipose tissue. Angiomyolipoma of the
kidney9,10 and liver,11 clear cell “sugar” tumor of the
lung,12,13 and lymphangiomyomatosis14,15 are all PEComas.
Hepatic PEComa most commonly occurs in females and is
partially associated with TSC in 6e10% of cases.11,16 TSC is
a group of autosomal-dominant genetic disorders caused by
germ-linemutations in theTSC1orTSC2 genes,which encode
the proteins hamartin and tuberin, respectively.17,18
The majority of the hepatic lesions are solitary. Multiple
PEComas of liver are extremely rare and usually occur in
tuberous sclerosis patients. In 1995, Nonomura et al19 first
reported two cases of multiple hepatic PEComas without
any neurologic manifestations or any radiologic features
suggestive of tuberous sclerosis. In recent years, analogous
cases have been reported.20 In our study, a 52-year-old
woman with multiple hepatic PEComas had two lesions
distributed in the left lobe and S8 of the liver. The size of
tumors was 4 cm  4 cm  2.5 cm, and
2.4 cm  2.0 cm  1.6 cm, respectively. The patient did not
have TSC and was asymptomatic.
Regardless of their location, this family of tumors
possesses similar immunohistochemical profiles, including
positivity formelanocytic (HMB-45) and smoothmuscle (SMA)
markers. The HMB-45 marker was first reported in both renal
and hepatic PEComas in 1991.21,22 Soon afterward, addi-
tional studies confirmed these findings. Both melanocytic
(HMB-45 and/or melan-A) and smooth muscle (muscle-
specific actin and/or desmin) markers are helpful forFigure 2 MR image of hepatic PEComa (arrows) complicated wit
weighted MR image showed a heterogeneous hypointense mass wi
showed the same lesions with heterogeneous hyperintensity. (C
heterogeneous hyperintensity in the liver lesion and moderate hy
phase, the lesions showed asymmetrical enhancement. MRZ magnconfirming the diagnosis.23,24 In the past, researchers
assumed that PEComas expressed both melanocytic and
smooth muscle markers at the same time. However, studies
show that only 80% of cases express both, so negative
expression of smooth muscle markers do not necessarily
exclude diagnosis of PEComas.25 Besides HMA-45 and SMA,
additional immunohistochemical markers including S-100,
CD34, and CD117 were detected. Detection of thesemarkers
was not completely coincidental.1,26,27 Li et al26 have re-
ported myoid cells positive for S-100 and CD34 in hepatic
PEComa. However, Paiva et al’s27 resultswere negative. In
our study, the tumor cells were immunoreactive for HMB-45
in five cases, for SMA in four cases, for vimentin in one
case, and for melan-A in two cases. The tumor cells were
negative for S100, hepatocyte, and CK8/18.
The variable proportions of the different components of
hepatic PEComa make diagnosis difficult prior to surgery. In
our study, one case was diagnosed with hepatic PEComa,
three cases with hepatocellular carcinoma, and one case
with hepatic adenomata. Histologically, the chief differ-
ential diagnostic considerations for hepatic PEComa are
metastatic gastrointestinal stromal tumor and malignant
melanoma, which include epithelioid cell, spindle cell, and
positive CD117 expression.28 The vast majority of PEComas
are benign, and the malignant form is extremely rare. Since
relatively few malignant PEComas have been reported, firm
criteria for malignancy have yet to be established. To date,
there are only four case reports documenting the malignant
form of hepatic PEComa,5,29,30 In a recent study, taking into
account their data and a review of the literature, Nguyen
et al summarize the similarities and differences betweenh renal PEComa (arrow heads) in a 37-year-old woman. (A) T1-
th well-demarcated tumor margins. (B) T2-weighted MR image
) T2-weighted fat-suppressed MR image showed moderately
pointensity in the renal lesion. (D) During the hepatic arterial
etic resonance; PEComaZ perivascular epithelioid cell tumor.
Figure 3 MR image of multiple hepatic perivascular epithelioid cell tumors in a 52-year-old woman. (A) T1-weighted MR image
showed a heterogeneous hypointense mass in the left lobe (arrows). (B) T2-weighted MR image showed the same lesions in the left
lobe with heterogeneous hyperintensity. (C) T2-weighted fat-suppressed MR image showed heterogeneous hyperintensity in the
liver lesion in the left lobe. (D) During the hepatic arterial phase, the lesions in the left lobe showed asymmetrical enhancement.
(E) T1-weighted MR image showed a heterogeneous hypointense mass in S8 (arrowheads). (F) T2-weighted MR image showed the
same lesions in S8 with heterogeneous hyperintensity. (G) T2-weighted fat-suppressed MR image showed heterogeneous hyper-
intensity in the liver lesion in S8. (H) During the hepatic arterial phase, the lesions in S8 showed asymmetrical enhancement.
MR Z magnetic resonance.
Hepatic perivascular epithelioid cell tumor 61benign and malignant hepatic PEComas. The consistent
features observed in all four cases include cytologic atypia
and coagulative necrosis.5 Although cytologic atypia is
usually a feature of malignant neoplasms, it is also present
in benign hepatic PEComa.31 Coagulative necrosis isFigure 4 Microscopic appearances of hepatic perivascular epith
muscle; hemorrhage in smooth muscle (H&E 100). (B) Smooth mus
Sheets of adipocytes webbed among smooth muscle cells (H
H&E Z hematoxylin and eosin.a consistent feature of malignant hepatic PEComa and
appears to be a reliable indicator of malignancy. In
proposing the features for malignant hepatic PEComa, this
analysis shows that cytologic atypia and an infiltrative
growth pattern are less important, whereas coagulativeelioid cell tumor. (A) Thick-walled blood vessels and smooth
cle cell surrounding thick-walled blood vessels (H&E 100). (C)
&E 100). (D) Extramedullary hematopoiesis (H&E 100).
Figure 5 Immunopathological characteristics of hepatic perivascular epithelioid cell tumor. (A) Human Melanoma Black-45 (SP
method, 100). (B) Smooth muscle actin (SP method, 100). (C) Melan-A (SP method, 100). (D) Vimentin (SP method, 100).
SP Z streptavidin peroxidase.
62 Z. Liu et al.necrosis, larger tumor size (>10 cm), negativity for CD117,
and clinical evidence of aggressive disease are more
important features.31
If the diagnosis of hepatic PEComa has been made
definitively by imaging techniques, fine needle aspiration,
or needle biopsy prior to operation, conservative treatment
may be recommended. But when the patient is having
symptoms, or when the risk of rupture is a possibility
because the lesion has increased in size significantly under
continued observation, surgical resection should be sug-
gested. In fact, the vast majority of patients with PEComas
received hepatectomy because of indefinable preoperative
diagnosis. In our study, all the five patients received
surgical resection.
Several studies have showed that angiomyolipomas in
patients with TSC or sporadic lymphangioleiomyomatosis
are associated with mutations in tuberous sclerosis genes
resulting in constitutive activation of the mammalian mTOR
(mammalian target of rapamycin). The drug sirolimus
suppresses mTOR signaling. Recently, Bissler
et alconducted a 24-month, nonrandomized, open-label
trial to determine whether an mTOR suppressor (sirolimus)
reduces the angiomyolipoma volume in patients with TSC or
sporadic lymphangioleiomyomatosis. The result indicates
that treatment with sirolimus decreases the size of angio-
myolipomas and improves lung function.32 Positivity of the
melanocytic markers S100 and HMB-45 suggests that this
tumor is derived from the pleuripotent stem cells of the
neural crest, as proposed by Sturtz et al5 and Nguyen et al.4
In conclusion, a correct preoperative diagnosis of
PEComa by imaging scans, needle biopsy, and other tech-
niques is difficult, especially in patients with a low fatcontent in hepatic PEComa. A more specific diagnostic is
needed. Despite considerable advances in our recognition
of this lesion, more cases with longer clinical follow-up
need to be evaluated in a systematic fashion. Ultimately,
further research will allow accurate prediction of the
behavior of this lesion and establish firm criteria for
discrimination between malignant and benign tumors.
Finally, further research into the etiology of PEComa may
yield new drug targets for treating this distinctive tumor.References
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